Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss
Importantly, research is now exploring the expansion of GLP-1RAs into the treatment of substance use disorders, including alcohol and nicotine dependence
Ozempic belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists
Abstract Abstract The increasing global prevalence of type 2 diabetes and obesity has led to rising use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Interaes medicamentosas Quando usados junto insulina ou sulfonilureias, os agonistas do GLP-1 elevam as chances de episdios de hipoglicemia
Individualized Assessment: The decision to use a GLP-1 inhibitor should be made on an individual basis, carefully weighing the potential benefits and risks, especially in the context of your mental health history
US$ 28.34
US$ 27.17
US$ 26.18
US$ 26.16
US$ 29.94
